Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis.

BACKGROUND

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non-cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.

OBJECTIVES

To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

METHODS

AE reports related to ADT drugs were extracted from FAERS (Q1 2004-Q3 2024). Disproportionality analyses-including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)-were conducted to identify significant cardiovascular safety signals.

RESULTS

Different ADT agents exhibited distinct cardiovascular AE profiles. Some drugs were linked to a broader range of CVD-related AEs, while others had more limited associations.

CONCLUSIONS

ADT agents demonstrate heterogeneous cardiotoxicity profiles. These findings emphasize the need for individualized treatment strategies, particularly in patients with pre-existing CVD risks, and may aid clinicians in balancing cancer control with cardiovascular safety.